Intravesical VAX014 Synergizes with PD-L1 Blockade to Enhance Local and Systemic Control of Bladder Cancer

Area of Science:

• Oncology
• Immunotherapy
• Cancer Research

Background:

• Combination immunotherapy is emerging for solid tumors, but data in advanced bladder cancer is limited.
• VAX014 is a novel bacterial minicell-based agent for intravesical bladder cancer treatment.
• PD-1/PD-L1 blockade is a key systemic immunotherapy strategy.

Purpose of the Study:

• To evaluate the antitumor activity and immune mechanisms of VAX014 in bladder cancer models.
• To investigate the efficacy of combining VAX014 with PD-L1 blockade.
• To assess the potential of this combination for advanced bladder cancer treatment.

Main Methods:

• Utilized syngeneic orthotopic bladder tumor models (MB49, MBT-2).
• Administered VAX014 intravesically and PD-L1 blockade systemically.
• Analyzed T cell responses (CD4+, CD8+), PD-L1 expression, and distal tumor clearance.
• Examined integrin expression in patient tumor biopsies and mouse models.

Main Results:

• VAX014's antitumor effect depended on CD4+ and CD8+ T cells.
• PD-L1 upregulation was an immune resistance mechanism in MB49 model.
• Combination therapy significantly improved tumor clearance and induced immunologic memory.
• Combination treatment led to systemic antitumor responses, clearing distal and metastatic tumors.
• Intratumoral CD4+ T cells shifted from regulatory to Th1, with increased activated CD8+ T cells and IFNγ.
• Target integrins (α3β1, α5β1) were overexpressed in advanced bladder cancer.

Conclusions:

• VAX014 combined with PD-L1 blockade demonstrates significant antitumor activity in preclinical bladder cancer models.
• This combination overcomes immune resistance and promotes systemic antitumor immunity.
• The findings support the clinical investigation of VAX014 and PD-1/PD-L1 blockade for advanced bladder cancer.